This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 45| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2040 | Promoter methylation of HCCS1 | RNAs | Human | NA | Diagnostic and Prognostic | HCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage | p < 0.001 | Serum | 28189396 |
| 2042 | AFP, Promoter methylation of HCCS1 | Protein and RNA | Human | NA | Diagnostic and Prognostic | HCC vs CHB (Chronic hepatitis B); significantly associated with tumor node-metastasis (TNM) stage | p < 0.05 | Serum | 28189396 |
| 2061 | cis-Aconitate acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
| 2063 | Progesterone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
| 2067 | Cortisone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
| 2086 | Estrone plus Estradiol/Testosterone ratio | Steroid | Human | Downregulated in liver cancer cell. | Diagnostic | Normal vs liver cancer | p < 0.06 | Serum | 27060391 |
| 2107 | Combination of S100A9 and GRN | Others | Human | Downregulated in HCC patients | Diagnostic and Prognostic | Normal vs HCC | p < 0.001 | Urine | 26675302 |
| 2120 | D-glucurono-6,3-lactone | Metabolites | Mice | Upregulated in AFLD | Potential Predictive * | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled | Serum | 24171385 | |
| 2127 | DNA hypomethylated regions of GPM6B | Epigenetic (Others) | Human | hypomethylated and Upregulated level in HCC | Diagnostic | Cancer v/s Normal | p < 0.01 | Tissue | 23950870 |
| 2128 | DNA hypomethylated regions of MAGEA12 | Epigenetic (Others) | Human | hypomethylated and Upregulated level in HCC | Diagnostic | Cancer v/s Normal | p < 0.01 | Tissue | 23950870 |
| 2129 | DNA hypomethylated regions of FCRL1 | Epigenetic (Others) | Human | hypomethylated and Upregulated level in HCC | Diagnostic | Invasive HCC v/s non-invasive HCC | p < 0.01 | Tissue | 23950870 |
| 2207 | NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) | Neutrophils and lyphocytes (Others) | Human | NLR and SII in patients associated with more advanced stages of HCC | Prognostic | Normal vs HCC; associated with TNM stage, PST and survival of patients | p < 0.05 | Blood | 29123264 |
| 2272 | GRP94 (Tumor rejection antigen 1) | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.59) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2284 | Heterogeneous nuclear ribonucleoprotein A2/B1 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.55) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2285 | 26S proteasome non-ATPase regulatory subunit 8 | Protein | Human | Downregulated in recurrence HCC than non-recurrence HCC (with fold change 0.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2288 | TCP-1 chaperonin cofactor A | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.57) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2291 | Nuclear chloride ion channel 27 | Protein | Human | Upregulated in recurrence HCC than non-recurrence HCC (with fold change 1.64) | Prognostic | Early recurrence v/s No recurrence HCC | p < 0.05 | Tissue | 17391314 |
| 2392 | Coagulation factor XIII | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2410 | Glutathione S-transferase θ1 | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2411 | Glutathione S-transferase | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2412 | Glutathione S-transferase M3 | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2413 | Glutathione S-transferase θ2 | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2414 | Monoamine oxidase A | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2415 | Chlordecone reductase | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2417 | Zeta-crystallin/quinone reductase | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11752456 |
| 2429 | reticulon 4 or RTN4 | RNAs | Human | Downregulated in HCC than non-tumor (with fold change of 2.8) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 16463013 |
| 2467 | GRP94, GRP78, GRP75, HSC71, HSP90, HSP70, HSP60, Aconitase, EF-2, Nucleophosmin, VIM, NDK-A, Argininosuccinate synthase, CPSASE-I, | Protein | Human | Differentially expressed (Argininosuccinate synthase, Carbamoyl-phosphate synthase (CPSASE I) are Downregulated and rest 12 are Upregulated) in HCC tumor v/s non-tumorous | Diagnostic | HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2468 | hnRNP K, HSP70RY, Lamin B1, 40S ribosomal protein SA, FTCD, SOD, Arginase, SMP-30, P5C dehydrogenase, Transitional endoplasmic reticulum ATPase, Ubiquitin carboxyl-terminal hydrolase 5, Thiosulfate sulfurtransferase (Rhodanese), Betaine-himocysteine S-methyltransferase, NCC27, FGB, RACK1, PDI, SARDH | Protein | Human | Differentially expressed (hnRNP K, HSP70 RY, Lamin B1, 40S ribosomal protein SA, Transitional endoplasmic reticulum ATPase, Ubiquitin carboxyl-terminal hydrolase 5, Rhodanese, Betaine-himocysteine S-methyltransferase, NCC27, Fibrinogen β chain, RACK1 are Upregulated and rest 12 are Downregulated) | Diagnostic | HBV associated HCC tumor v/s non-tumorous | p < 0.05 | Tissue | 14654528 |
| 2503 | Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Tr | RNAs | Human | Diffrenetially expressed in HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 11973655 |
| 2505 | Lactate dehydrogenase, aldehyde oxidase, nucleoside diphosphate kinase, alpha 1 catenin, beta catenin, transforming protein rho B, IgG, IgGK, IgG3, IgG1, IgG1K, IgA1, IgHA, IgG1-Fc, Collagen - alpha 1 subunit, c-jun N-terminal kinase 2, ADP/ATP carrier protein, Progression receptor associated protei | RNAs | Human | Diffrenetially expressed in cirrhotic v/s non-cirrhotic | Diagnostic | cirrhotic v/s non-cirrhotic | p < 0.01 | Tissue | 11973655 |
| 2506 | Zinc finger protein, integrin alpha 6, hepatoma derived growth factor, TGF beta induced, Macrophage inhibitory cytokine 1, lymphocyte antigen, aldehyde oxidase, c-myc purine binding transcription factor puf, plasminogen, vitronectin, hemoglobin alpha subunit, cytosolic superoxide dismutase, methylen | RNAs | Human | Diffrenetially expressed in moderately differentiated HCC v/s poorly differentiated HCC | Diagnostic | moderately differentiated HCC v/s poorly differentiated HCC | p < 0.01 | Tissue | 11973655 |
| 2525 | Cytoplasmic dynein light chain, Hepatoma-derived growth factor, Ribosomal protein L6, glutathioneS-transferase, Fibronectin, Ras homolog gene family member B, TR3 orphan receptor, c-myc transcription factor (puf), MHC-class IC | RNAs | Human | Upregulated in HCC than non-tumorous tissue ( with average ratio more than 2) | Diagnostic | HCC v/s non-tumor | NA | Tissue | 11283847 |
| 2526 | Plasminogen, Corticotropin releasing hormone bindingprotein, GRO2 oncogene, Interferon gamma-inducible protein 10, alpha-Platelet-derived growth factor receptor precursor, Cell division cycle 25C, Cytochrome P450-IIC, Human intercrine-a(hIRH), IL-8 | RNAs | Human | Downregulated in HCC than non-tumorous tissue ( with average ratio more than 2) | Diagnostic | HCC v/s non-tumor | NA | Tissue | 11283847 |
| 2531 | TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, | RNAs | Human | 7 genes Downregulated i.e. CYP1A2, Human-alpha1-antitrypsin gene (S variant) complete cds, PCOLCE, CNP, DXYS155E, CLECSF14, TRIM25 and 29 get upregulated in | Diagnostic and prognostic | Single nodular HCC group v/s multicentric HCC group; associated with multicentric recurrence | p < 0.05 | Tissue | 16788756 |
| 2547 | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP | RNAs | Human | 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2551 | Isocitrate dehydrogenase [NADP] (cytoplasmic), Fumarate hydratase (mitochondrial), Enoyl-CoA hydratase (mitochondrial), Betaine-homocysteine S-methyltransferase, Serotransferrin precursor | Protein | Human | Downregulated in well-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |
| 2553 | Keratin type I cytoskeletal 10, Catalase, Aldehyde dehydrogenase (mitochondrial), GlutathioneS-transferase A1, Antioxidant protein 2, Isocitrate dehydrogenase [NADP] (cytoplasmic), Formiminotransferase-cyclodeaminase, Carbonic anhydrase I, Fructose bisphosphate aldolase B, Arginase 1, Fructose-1, 6- | Protein | Human | Downregulated in poorly-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |
| 2554 | sterol-C5-desaturase, Peroxisomal phytanoyl-CoA alpha-hydroxylase, Homo sapiens clone 23915, Osteopontin 5/6 0, Full-length cDNA clone ZD66D02, Senescence-associated epithelial membrane protein(SEMP1), Human DNA topoisomerase II (top2) mRNA, Homo sapiens lysosomal membrane glycoprotein-2 (LAMP2), Hu | RNAs | Human | Upregulated in HCC than non-tumor | Diagnostic | Tumor v/s normal | NA | Tissue | 12136251 |
| 2562 | galectin-3,serine/threonine kinase, translation factor eIF- 4A, -4B, -3, fibroblast growth factor receptor, and ri- bosomal protein L35A | RNAs | Human | Upregulated in HCC | Diagnostic | HCC v/s non-tumor | Tissue | 12521301 | |
| 2566 | Matrixmetalloproteinase14 or MMP14, MT-MMP1,osteonectin/SPARC | RNAs | Human | Upregulated in all three tested HCC samples. | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11813304 |
| 2574 | NFIB,GFI1,TAF1,ONECUT1,BTF,andTRIM32 | RNAs | Human | Upregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2580 | Dystrophin, Homolog to tubulin beta chain, Zinc finger protein 337, Friedreich ataxia region gene X123, Fibronectin (Alt. Splice 1), Zinc finger protein 9, Metallothionein IV, Poly(rC) binding protein 3, KIAA0426 gene product, Hypothetical protein FLJ13910, RAN binding protein 2 like 1, S100 calcium | RNAs | Human | Downregulated in L1 than L0 (with fisher ratio more than 9.74) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2581 | Cystatin C, Prolylcarboxypeptidase (angiotensinase C), Lysyl-tRNA synthetase, Voltage-dependent anion channel 3, Protective protein for beta-galactosidase (cathepsin A), Interferon gamma-inducible protein 30, Signal sequence receptor delta, Thioredoxin-related transmembrane protein, Cathepsin D, Ras | RNAs | Human | Upregulated in L1 than L0 (with Fisher ratio more than 8.9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2582 | Mannose receptor C type 1, BCL2/adenovirus E1B 19 kD interacting protein 3 like, v-fos FBJ murine osteosarcoma viral oncogene homolog, Ficolin 3 (Hakata antigen), Calmodulin 1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog, Metallothionein 1H, Metallothionein 1E, Solute carrier family 31 me | RNAs | Human | Downregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2586 | APOC1, SEPP1, PDZGEF1, SCML2, ALDH5A1, BNIP3, FBXW1B, PAH, Homo sapiens clone 24473 mRNA sequence, PACE4, FLJ31305 fis or clone LIVER1000104 or , Unknown or , MIG2, RARRES2, BAAT, KDELR2, RNP24, FACL2, KIAA0977 protein, HADHSC, HADHSC, SDHD, CPB2, PGRMC1, AOP2, PPM1A, SDC1, CCL14, EST | RNAs | Human | Downregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |